Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens
暂无分享,去创建一个
Frédérique Jacobs | Fabio Silvio Taccone | Jason A. Roberts | J. Vincent | F. Taccone | F. Jacobs | J. Roberts | A. Udy | J. Lipman | Jean-Louis Vincent | Jeffrey Lipman | Andrew A. Udy
[1] Jerome J. Schentag,et al. Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.
[2] Joshua A. Doherty,et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. , 2006, Chest.
[3] J. Roberts,et al. Pharmacokinetic issues for antibiotics in the critically ill patient , 2009, Critical care medicine.
[4] M. Rybak,et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] K. Ho,et al. Risk Factors and Outcomes of Methicillin-resistant Staphylococcus Aureus Bacteraemia in Critically Ill Patients: A Case Control Study , 2009, Anaesthesia and intensive care.
[6] K. Haase,et al. Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections , 2010, Expert review of anti-infective therapy.
[7] N H Holford,et al. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. , 1999, Computer methods and programs in biomedicine.
[8] F. Pea,et al. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. , 2000, The Journal of antimicrobial chemotherapy.
[9] G Sherman,et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.
[10] M. Cooper,et al. Methicillin-resistant Staphylococcus aureus in the critically ill. , 2004, British journal of anaesthesia.
[11] D. Levine,et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] P. Viale,et al. Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients , 2009, Antimicrobial Agents and Chemotherapy.
[13] T. Similowski,et al. Continuous versus Intermittent Infusion of Vancomycin in Severe Staphylococcal Infections: Prospective Multicenter Randomized Study , 2001, Antimicrobial Agents and Chemotherapy.
[14] A. Jeurissen,et al. A higher dose of vancomycin in continuous infusion is needed in critically ill patients. , 2011, International journal of antimicrobial agents.
[15] P. Marik. Aminoglycoside Volume of Distribution and Illness Severity in Critically Ill Septic Patients , 1993, Anaesthesia and intensive care.
[16] J. Garnacho-Montero,et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.
[17] J. Bédos,et al. Methicillin-resistant Staphylococcus aureus pneumonia treatment: do not confuse pharmacokinetics and pharmacodynamics. , 2007, Chest.
[18] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[19] N. Holford,et al. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. , 2004, British journal of clinical pharmacology.
[20] J. Jernigan,et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. , 2009, JAMA.
[21] A. Sánchez Navarro,et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients , 2007, Intensive Care Medicine.
[22] J. Vincent,et al. Comparison of dopamine and norepinephrine in the treatment of shock. , 2010, The New England journal of medicine.
[23] R. Bellomo,et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units , 2004, Intensive Care Medicine.
[24] N. V. Jiménez-Torres,et al. Population pharmacokinetic parameters of vancomycin in critically ill patients , 2006, Journal of clinical pharmacy and therapeutics.
[25] E. Draper,et al. APACHE II: A severity of disease classification system , 1985, Critical care medicine.
[26] F. Colardyn,et al. Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. , 2002, Archives of internal medicine.
[27] 理 福田,et al. University of California, San Francisco , 1974, Medical History.
[28] George L. Drusano,et al. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.
[29] L. Bauer,et al. Vancomycin dosing in morbidly obese patients , 1998, European Journal of Clinical Pharmacology.
[30] D. Alexander,et al. Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration , 2009 .
[31] K. Wood,et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.
[32] C. Sprung,et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.